华芢生物成立13年来无药上市 背负对赌协议闯关港交所

每日经济新闻
Yesterday

每经记者:鄢银婵每经编辑:文多经过13年漫长研发、数亿元持续投入,华芢生物仍徘徊在“三无”(没有稳定收入,没有商业化产品,没有盈利)十字路口。《每日经济新闻》记者注意到,这家专注于血小板衍生生长因子(PDGF)药物研发的生物科技企业,被寄望填补国产空白,但公司同时面临行政开支高企、对赌上市的压力。在董事薪酬2024年上涨的另一面,则是核心产品尚未获批、市场规模存在天花板等现实。如今,华芢生物冲刺...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10